A complete application in a minute
Tailored resume and cover letter, ready to send.
Henlius USA Inc. seeks Medical Science Liaisons to engage scientifically with KOLs and HCPs across targeted therapeutic areas on the East Coast and Centrally in the US.
This field-based role requires delivering medical education, supporting clinical trials, and representing Henlius to external scientific communities. The MSL will maintain deep therapeutic knowledge, communicate complex data clearly, and collaborate with clinical development, commercial, and marketing teams to align medical
Henlius is a global, innovation-driven, and patient-centric biopharmaceutical company committed to delivering high-quality biologic therapies to patients worldwide. We are looking for MSL's located Centrally or on the East Coast. Medical Science Liaisons (MSL) are a field-based team of scientists who function as an extension of the US Medical Affairs department. MSLs are responsible for developing professional relationships with the healthcare community to provide medical education for approved and experimental therapeutics in alignment with medical affairs strategy. MSLs provide medical information through scientific exchange, clinical/scientific support of clinical trials, and serve as external-facing scientific experts representing Henlius and its products.
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 10 products have been approved for marketing worldwide, and 5 marketing applications have been accepted for review in China and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.
Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world's first anti-PD-1 mAb for the first-line treatment of SCLC, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANLIKANG (rituximab), the first China-developed biosimilar, denosumab Bildyos® and Bilprevda®, and pertuzumab Poherdy®. What's more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.
For more information, please visit https://www.henlius.com/en/Index.html